4.1 Article

Willingness to pay for QALY: perspectives and contexts in Japan

Journal

JOURNAL OF MEDICAL ECONOMICS
Volume 22, Issue 10, Pages 1041-1046

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/13696998.2019.1639186

Keywords

Quality-adjusted life years; willingness-to-pay; health technology assessment; incremental cost-effectiveness ratio; Japan

Ask authors/readers for more resources

Objectives: Theoretically, willingness-to-pay (WTP) for quality-adjusted life years (QALY) can vary depending on social and personal preferences and on ex-ante and ex-post settings. However, empirical investigations into the theoretical differences are lacking. In Japan, setting the threshold has been controversial since a pilot project to implement health technology assessments (HTA) launched in 2016. The study aim is to estimate WTP values for one additional QALY from different perspectives, health statuses, and contexts to confirm the difficulty in setting a uniform price threshold using WTP. Methods: More than 1,000 respondents representing a cross-section of the Japanese population answered each of nine questionnaire decks in an online panel. WTP values were estimated on three different perspectives (personal, social, and socially inclusive) and on two contexts (ex-ante and ex-post). This study primarily used the non-parametric spike model based on double-bounded dichotomous choice (DBDC) settings to obtain the conditional WTP values. Results: WTP per QALY was higher in the severe health status than in the moderate health status from all perspectives. Respondents from the socially inclusive perspective estimated the highest WTP value for a new drug. Respondents were also asked about life-threatening diseases in ex-post and ex-ante. The WTP value in ex-ante was higher than in ex-post, and demographic factors affecting the WTP were different in both situations. The various WTP values were obtained from these surveys. Limitations: The analysis was based on data collected from an internet panel, which could be biased. There is also a risk that respondents answered the questionnaire differently if asked in everyday situations. Conclusion: Use of a uniform price threshold may not be appropriate in policy settings, because it may not reflect diverse preferences based on different situations, such as disease type and severity. Setting a price threshold as Japan institutes an HTA system requires further research.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Immunology

Public preferences and willingness to accept a hypothetical vaccine to prevent a pandemic in Japan: a conjoint analysis

Ataru Igarashi, Yosuke Nakano, Mariko Yoneyama-Hirozane

Summary: This research investigated the willingness of Japanese individuals to be vaccinated against a hypothetical infectious disease during the COVID-19 pandemic. The study results can influence vaccine-related policy and pandemic preparedness, and help governments consider public intention to prepare health communication campaigns that encourage vaccination.

EXPERT REVIEW OF VACCINES (2022)

Article Economics

Impact of reimbursement restriction on drug market sales under the National Health Insurance in Japan

Hiroaki Mamiya, Ataru Igarashi

Summary: This study aims to investigate the impact of reimbursement restrictions on drug market sales in Japan, especially in situations where health technology assessment or other market access regulations are not applicable before market entry.

JOURNAL OF MEDICAL ECONOMICS (2022)

Article Economics

The impact of omalizumab on paid and unpaid work productivity among severe Japanese cedar pollinosis (JCP) patients

M. Mueller, A. Igarashi, K. Hashiguchi, M. Kappel, F. Paolini, H. Yoshisue, M. Funakubo, H. Sharma, M. Okano

Summary: This study estimates the effect of omalizumab on paid and unpaid work activities in patients with severe and most severe JCP symptoms in Japan. Results show that the use of omalizumab might reduce the paid and unpaid work productivity losses due to severe and most severe JCP by nearly one-third.

JOURNAL OF MEDICAL ECONOMICS (2022)

Article Endocrinology & Metabolism

Cost-Effectiveness Analysis of Initiating Type 2 Diabetes Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor Versus Conventional Therapy in Japan

Ataru Igarashi, Keiko Maruyama-Sakurai, Anna Kubota, Hiroki Akiyama, Toshitaka Yajima, Shun Kohsaka, Hiroaki Miyata

Summary: This study evaluated the cost-effectiveness of initiating antidiabetic therapy with an SGLT2i. The results show that treatment with SGLT2i can improve clinical outcomes and reduce the economic burden of type 2 diabetes mellitus.

DIABETES THERAPY (2022)

Review Medicine, Research & Experimental

Efficacy of Low-Dose Estrogen-Progestins and Progestins in Japanese Women with Dysmenorrhea: A Systematic Review and Network Meta-analysis

Masaru Iwata, Yoshihiro Oikawa, Yutaka Shimizu, Naotaka Sakashita, Ayako Shoji, Ataru Igarashi, Yutaka Osuga

Summary: This study confirmed the effectiveness of low-dose estrogen-progestins and dienogest for primary and secondary dysmenorrhea. Continuous progestin regimens may be more effective than cyclic regimens in improving outcomes according to the results of meta-analysis and network meta-analysis.

ADVANCES IN THERAPY (2022)

Article Multidisciplinary Sciences

Health state utilities of patients with hepatitis B and C and hepatitis-related conditions in Japan

Hiroki Sugimori, Maki Hirao, Ataru Igarashi, Hiroshi Yatsuhashi, Shunya Ikeda, Naohiko Masaki, Hiroshi Yotsuyanagi, Takeshi Yoda, Takeshi Odajima, Tomoyuki Takura, Tomohiro Hirao

Summary: This study comprehensively assessed the health state utilities of patients with HB, HC, and hepatitis-related conditions in Japan using a nationwide survey. Self-administered questionnaires and expert estimations were used to determine the utilities of different disease conditions.

SCIENTIFIC REPORTS (2022)

Review Health Care Sciences & Services

Value assessment of new interventions for Alzheimer's disease dementia in Japan based on literature review and group interview

Ataru Igarashi, Shunya Ikeda

Summary: This article proposes an optimal way to assess the disease burden and treatment value of Alzheimer's disease dementia (ADD) in Japan, which includes patient quality of life, medical costs, caregiver quality of life, public long-term care costs, and informal care costs. It also highlights the limitations of measuring QOL, the importance of including public long-term care costs and informal care costs in the assessment, and the recognition of other elements of care burden that cannot be quantitatively measured.

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2022)

Article Oncology

Factors associated with financial toxicity in patients with breast cancer in Japan: a comparison of patient and physician perspectives

Sumito Saeki, Tsuguo Iwatani, Atsuko Kitano, Naomi Sakurai, Yuko Tanabe, Chikako Yamauchi, Ataru Igarashi, Yusuke Kajimoto, Sayaka Kuba, Fumikata Hara, Yasuaki Sagara, Sumito Saeki

Summary: This study examined the financial toxicity (FT) in patients with breast cancer in Japan and presented an overview of the findings. The study found that recent payments, cancer stage, and related departments had the highest impact on FT. Factors such as income, age, and family support were found to negatively affect FT. The study also revealed a significant discrepancy in perceived information support between patients and physicians.

BREAST CANCER (2023)

Article Medicine, General & Internal

Prevalence of multimorbidity and its associations with hospitalisation or death in Japan 2014-2019: a retrospective cohort study using nationwide medical claims data in the middle-aged generation

Yoshiyuki Saito, Ataru Igarashi, Takeo Nakayama, Shingo Fukuma

Summary: This study investigated the prevalence of multimorbidity and its association with clinical outcomes in different age groups in Japan. The results showed that multimorbidity is already common in the middle-aged population and is associated with poor clinical outcomes. These findings highlight the importance of multimorbidity and the urgent need for preventive intervention at the public healthcare level.

BMJ OPEN (2023)

Review Health Care Sciences & Services

Value elements and methods of value-based pricing for drugs in Japan: a systematic review

Akina Takami, Masafumi Kato, Hisato Deguchi, Ataru Igarashi

Summary: This article investigates the value elements and pricing method for value-based pricing (VBP) and finds that there is no consensus on specific value elements and pricing methods. Some studies used the cost-effectiveness analysis approach, while others used different approaches, quantifying broader value elements with individual methods. Further research is needed to establish a VBP method that incorporates broader values.

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2023)

Article Economics

Preferences and values for government policies on infectious disease outbreaks and epidemics for the Japanese population: a conjoint analysis

Ippei Morita, Kenji Kurazono, Manami Yoshida, Shinzo Hiroi, Kosuke Iwasaki, Tomomi Takeshima, Chise Ha, Ataru Igarashi

Summary: This study aimed to investigate the preferences of the Japanese population regarding government policies for addressing infectious disease outbreaks. The results showed that the accessibility of tests, vaccines, and therapeutic drugs was preferred, with easily accessible therapeutic drugs being the most preferred option.

JOURNAL OF MEDICAL ECONOMICS (2023)

Article Virology

Inpatient and outpatient costs associated with respiratory syncytial virus in Japanese infants and older adults

Ataru Igarashi, Kanae Togo, Yasuhiro Kobayashi, Kazumasa Kamei, Naohiro Yonemoto, Naruhiko Ishiwada

Summary: This study evaluated the healthcare resource use and cost of treating respiratory syncytial virus (RSV) in infants and older adults in Japan. The findings showed that the cost of treating RSV in hospitalized older adults was significantly higher than in hospitalized infants, while the total cost for non-hospitalized patients was higher in infants. Additionally, the use of palivizumab, a medication for infants, was also found to be costly.

FUTURE VIROLOGY (2023)

Correction Oncology

Factors associated with financial toxicity in patients with breast cancer in Japan: a comparison of patient and physician perspectives (Jun, 10.1007/s12282-023-01476-z, 2023)

Sumito Saeki, Tsuguo Iwatani, Atsuko Kitano, Naomi Sakurai, Yuko Tanabe, Chikako Yamauchi, Ataru Igarashi, Yusuke Kajimoto, Sayaka Kuba, Fumikata Hara, Yasuaki Sagara, Shinji Ohno, Collaborative Study Grp of Sci Res, Japanese Breast Canc Soc

BREAST CANCER (2023)

Article Social Sciences, Interdisciplinary

Health-Related Quality of Life during COVID-19 Pandemic: Assessing Impacts of Job Loss and Financial Support Programs in Japan

Takaaki Ikeda, Ataru Igarashi, Satomi Odani, Masayasu Murakami, Takahiro Tabuchi

Summary: Job loss during the COVID-19 pandemic is negatively associated with health-related quality of life (HRQOL), while universal financial support is positively associated with HRQOL.

APPLIED RESEARCH IN QUALITY OF LIFE (2022)

No Data Available